sotalol has been researched along with Myocardial Ischemia in 29 studies
Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4." | 9.11 | Amiodarone versus sotalol for atrial fibrillation. ( Atwood, JE; Ezekowitz, MD; Fletcher, RD; Harris, CL; Jacobson, AK; Lewis, HD; Lopez, B; Raisch, DW; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2005) |
| "The purpose of this study was to investigate, in an anesthetized pig model of low-flow myocardial ischemia, the electrophysiologic effects of the class III drug d-sotalol during myocardial ischemia." | 7.70 | Ischemia-induced action potential shortening is blunted by d-sotalol in a pig model of reversible myocardial ischemia. ( Geelen, P; Gilbert, M; O'Hara, GE; Philippon, F; Plante, S; Turgeon, J, 2000) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 7.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| "In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4." | 5.11 | Amiodarone versus sotalol for atrial fibrillation. ( Atwood, JE; Ezekowitz, MD; Fletcher, RD; Harris, CL; Jacobson, AK; Lewis, HD; Lopez, B; Raisch, DW; Reda, DJ; Sharma, SC; Singh, BN; Singh, SN; Tang, XC, 2005) |
| "Considering the Survival With ORal D-sotalol (SWORD) study results, in which mortality was higher in patients treated by the pure class III agent D-sotalol, we tested DL- and D-sotalol (5 and 10 microM) in an in vitro model of "border zone" arrhythmias." | 3.70 | Proarrhythmic effects of DL- and D-sotalol on the "border zone" between normal and ischemic regions of isolated ventricular myocardium and antiarrhythmic effects on reperfusion. ( Ducouret, P; Flais, F; Gérard, JL; Libersa, C; Monti, F; Picard, S; Puddu, PE; Rouet, R, 1998) |
| "The purpose of this study was to investigate, in an anesthetized pig model of low-flow myocardial ischemia, the electrophysiologic effects of the class III drug d-sotalol during myocardial ischemia." | 3.70 | Ischemia-induced action potential shortening is blunted by d-sotalol in a pig model of reversible myocardial ischemia. ( Geelen, P; Gilbert, M; O'Hara, GE; Philippon, F; Plante, S; Turgeon, J, 2000) |
| "We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs." | 3.69 | Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995) |
| " The time to onset of the first arrhythmia and ventricular fibrillation, induced by intravenous infusion of ouabain, was shortened in the presence of AM 92016." | 3.69 | The in-vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016. ( Hagerty, MJ; Kane, KA; Wainwright, CL, 1996) |
| " Adverse events, deemed to be treatment related, were seen in 2." | 2.70 | A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. ( Biffi, M; Borggrefe, M; Boriani, G; Brachmann, J; Butrous, GS; Capucci, A; Kornacewicz-Jack, Z; Lubinski, A; Niederle, R; Wnuk-Wojnar, AM, 2001) |
| "A group of 57 patients with ischemic heart disease and inducible ventricular tachycardia (VT) at electrophysiological study (EPS) were selected from a population enrolled in a randomized double-blind crossover study of dofetilide (500 micrograms bid) versus sotalol (160 mg bid)." | 2.69 | Repolarization changes in a double-blind crossover study of dofetilide versus sotalol in the treatment of ventricular tachycardia. ( Bacchi, L; Biffi, M; Bitonti, F; Boriani, G; Branzi, A; Butrous, G; De Simone, N; Martignani, C; Zannoli, R, 2000) |
| "Acute episodes of arrhythmia are managed by bolus administration of Sotahexal [correction of Hexal]." | 2.68 | [Sotahexal pharmacodynamics in patients with ischemic heart disease]. ( Avdeĭchuk, ED; Bezprozvannyĭ, AB; Chestukhin, VV; Dorofeeva, EIu; Gorshkov, VA; Kesarev, GV; Lazutina, OM; Lyskovtsev, VV; Nesvetov, VN; Radzevich, AE, 1997) |
| "Ranolazine is a drug that exerts antianginal and antiischemic effects and also acts as an antiarrhythmic in isolation and in combination with other class III medications." | 1.37 | Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. ( Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP, 2011) |
| "dl-Sotalol abolished arrhythmias in ischemia and reduced the incidence of reperfusion arrhythmias to 30%." | 1.29 | Pro- and antiarrhythmic effects of d-sotalol and dl-sotalol in an isolated tissue model of ischemia and reperfusion. ( Ferrier, GR; Pasnani, JS, 1994) |
| "Sotalol was orally used in dose 160 mg/day during 6 weeks." | 1.29 | [The effects of long-term treatment of sotalol hydrochloride on time and frequency domain parameters of signal averaged electrocardiogram in patients with ischemic heart disease]. ( Banasiak, W; Bobak, J; Jagielski, J; Kałka, D; Ponikowski, P; Telichowski, A; Telichowski, C, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (58.62) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 2 (6.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dobrev, D | 1 |
| Aguilar, M | 1 |
| Heijman, J | 1 |
| Guichard, JB | 1 |
| Nattel, S | 1 |
| Bunch, TJ | 1 |
| Mahapatra, S | 1 |
| Murdock, D | 1 |
| Molden, J | 1 |
| Weiss, JP | 1 |
| May, HT | 1 |
| Bair, TL | 1 |
| Mader, KM | 1 |
| Crandall, BG | 1 |
| Day, JD | 1 |
| Osborn, JS | 1 |
| Muhlestein, JB | 1 |
| Lappe, DL | 1 |
| Anderson, JL | 1 |
| Singh, BN | 1 |
| Singh, SN | 1 |
| Reda, DJ | 1 |
| Tang, XC | 1 |
| Lopez, B | 1 |
| Harris, CL | 1 |
| Fletcher, RD | 1 |
| Sharma, SC | 1 |
| Atwood, JE | 1 |
| Jacobson, AK | 1 |
| Lewis, HD | 1 |
| Raisch, DW | 1 |
| Ezekowitz, MD | 1 |
| Ritchie, RH | 3 |
| Zeitz, CJ | 1 |
| Wuttke, RD | 1 |
| Hii, JT | 2 |
| Horowitz, JD | 3 |
| Furushima, H | 1 |
| Chinushi, M | 1 |
| Okamura, K | 1 |
| Komura, S | 1 |
| Tanabe, Y | 1 |
| Sato, A | 1 |
| Izumi, D | 1 |
| Aizawa, Y | 1 |
| Patterson, E | 1 |
| Scherlag, BJ | 1 |
| Lazzara, R | 1 |
| Garrison, GL | 1 |
| Berlin, KD | 1 |
| McIntosh, MA | 1 |
| Tanira, M | 1 |
| Pacini, D | 1 |
| Kane, KA | 2 |
| Pasnani, JS | 1 |
| Ferrier, GR | 1 |
| Bellemin-Baurreau, J | 1 |
| Poizot, A | 1 |
| Hicks, PE | 1 |
| Armstrong, JM | 1 |
| MacKenzie, I | 1 |
| Saville, VL | 1 |
| Waterfall, JF | 1 |
| Leibowitz, D | 1 |
| Yao, Z | 1 |
| Cavero, I | 1 |
| Gross, GJ | 1 |
| Zhang, YI | 1 |
| Finance, O | 1 |
| Manning, A | 1 |
| Chatelain, P | 1 |
| Vanoli, E | 1 |
| Hull, SS | 1 |
| Adamson, PB | 1 |
| Foreman, RD | 1 |
| Schwartz, PJ | 2 |
| Bobak, J | 1 |
| Banasiak, W | 1 |
| Telichowski, A | 1 |
| Ponikowski, P | 1 |
| Kałka, D | 1 |
| Jagielski, J | 1 |
| Telichowski, C | 1 |
| Hagerty, MJ | 1 |
| Wainwright, CL | 1 |
| Neuzner, J | 1 |
| Bahawar, H | 1 |
| Berkowitsch, A | 1 |
| Michel, U | 1 |
| Schlepper, M | 1 |
| Pitschner, HF | 1 |
| Dorofeeva, EIu | 1 |
| Gorshkov, VA | 1 |
| Chestukhin, VV | 1 |
| Lyskovtsev, VV | 1 |
| Bezprozvannyĭ, AB | 1 |
| Avdeĭchuk, ED | 1 |
| Kesarev, GV | 1 |
| Lazutina, OM | 1 |
| Nesvetov, VN | 1 |
| Radzevich, AE | 1 |
| Picard, S | 1 |
| Rouet, R | 1 |
| Monti, F | 1 |
| Puddu, PE | 1 |
| Ducouret, P | 1 |
| Flais, F | 1 |
| Libersa, C | 1 |
| Gérard, JL | 1 |
| Sallustio, BC | 1 |
| Owens, P | 1 |
| O'Brien, E | 1 |
| Geelen, P | 1 |
| O'Hara, GE | 1 |
| Plante, S | 1 |
| Philippon, F | 1 |
| Gilbert, M | 1 |
| Turgeon, J | 1 |
| Baczkó, I | 1 |
| El-Reyani, NE | 1 |
| Farkas, A | 1 |
| Virág, L | 1 |
| Iost, N | 1 |
| Leprán, I | 1 |
| Mátyus, P | 1 |
| Varró, A | 1 |
| Papp, JG | 1 |
| Boriani, G | 3 |
| Biffi, M | 3 |
| De Simone, N | 1 |
| Bacchi, L | 2 |
| Martignani, C | 2 |
| Bitonti, F | 1 |
| Zannoli, R | 2 |
| Butrous, G | 1 |
| Branzi, A | 2 |
| Spear, JF | 1 |
| Moore, EN | 1 |
| Lubinski, A | 1 |
| Capucci, A | 1 |
| Niederle, R | 1 |
| Kornacewicz-Jack, Z | 1 |
| Wnuk-Wojnar, AM | 1 |
| Borggrefe, M | 1 |
| Brachmann, J | 1 |
| Butrous, GS | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Association of Postoperative Lactate Levels With Postoperative Atrial Fibrillation in Patients Undergoing Isolated Coronary Artery Bypass Graft Surgery[NCT05448521] | 250 participants (Anticipated) | Observational | 2022-08-15 | Recruiting | |||
| Statin Therapy With Atorvastatin in Surgical Aortic Valve Replacement - a Randomized Controlled Trial[NCT05076019] | 266 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins - Randomized Controlled Trial[NCT05062239] | 100 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | |||
| First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication[NCT05939076] | Phase 3 | 220 participants (Anticipated) | Interventional | 2023-08-21 | Not yet recruiting | ||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation[NCT02145546] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-05-31 | Not yet recruiting | ||
| Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias[NCT03413150] | 80 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for sotalol and Myocardial Ischemia
| Article | Year |
|---|---|
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Postoperative atrial fibrillation: mechanisms, manifestations and management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Calci | 2019 |
Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.
Topics: Arrhythmias, Cardiac; Heart Ventricles; Hemodynamics; Humans; Myocardial Ischemia; Sotalol; Tachycar | 1993 |
8 trials available for sotalol and Myocardial Ischemia
| Article | Year |
|---|---|
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Amiodarone versus sotalol for atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Disease-Free Survival; Double-Blind M | 2005 |
Effect of dl-sotalol on mortality and recurrence of ventricular tachyarrhythmias: ischemic compared to nonischemic cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Comorbidity; Female; Humans; Incidence; Japan; Male; | 2007 |
Postextrasystolic potentiation in patients with ischaemic heart disease: influence of inotropic agents.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Cardiac Complexes, Premature; Cardiotonic Agents; Female; | 1995 |
[Prevention of sudden death in myocardial infarct: do experimental results help to understand the clinical reality? The case of the clinical trial SWORD (Survival With ORal D-sotalol)].
Topics: Acute Disease; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Drug Therapy, Combination; Femal | 1996 |
[Sotahexal pharmacodynamics in patients with ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Anti-Arrhythmia Agents; Arrhyt | 1997 |
Repolarization changes in a double-blind crossover study of dofetilide versus sotalol in the treatment of ventricular tachycardia.
Topics: Anti-Arrhythmia Agents; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans | 2000 |
A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; | 2001 |
A randomised cross-over study on the haemodynamic effects of oral dofetilide compared with oral sotalol in patients with ischaemic heart disease and sustained ventricular tachycardia.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cross-Over Studies; Hemodynamics; Humans; Middle | 2002 |
19 other studies available for sotalol and Myocardial Ischemia
| Article | Year |
|---|---|
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Topics: Acetanilides; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Cohort Studies; Def | 2011 |
Attenuation of the negative inotropic effects of metoprolol at short cycle lengths in humans: comparison with sotalol and verapamil.
Topics: Aged; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiac Pacing, Artificial; Female; Hemodynam | 2006 |
Electrophysiologic actions of d,l-sotalol and GLG-V-13 in ischemically injured canine epicardium.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Bridged Bicyclo Compounds, Heterocyclic; Coronar | 2007 |
Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia.
Topics: Animals; Anti-Arrhythmia Agents; Hydantoins; Imidazoles; Imidazolidines; In Vitro Techniques; Myocar | 1994 |
Pro- and antiarrhythmic effects of d-sotalol and dl-sotalol in an isolated tissue model of ischemia and reperfusion.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Guinea Pigs; Heart Conduction System; In Vitro Tec | 1994 |
An in vitro method for the evaluation of antiarrhythmic and antiischemic agents by using programmed electrical stimulation of rabbit heart.
Topics: Animals; Disease Models, Animal; Drug Evaluation, Preclinical; Electric Stimulation; Glycine; Heart; | 1994 |
Differential class III and glibenclamide effects on action potential duration in guinea-pig papillary muscle during normoxia and hypoxia/ischaemia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Electrophysiology; Glyburide; Guinea Pigs; Heart | 1993 |
Activation of cardiac KATP channels: an endogenous protective mechanism during repetitive ischemia.
Topics: Action Potentials; Adenosine Triphosphate; Animals; Coronary Circulation; Dogs; Female; Glyburide; H | 1993 |
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans | 1995 |
K+ channel blockade in the prevention of ventricular fibrillation in dogs with acute ischemia and enhanced sympathetic activity.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Dogs; Electrocardiography; Heart Rate; Myocardial I | 1995 |
[The effects of long-term treatment of sotalol hydrochloride on time and frequency domain parameters of signal averaged electrocardiogram in patients with ischemic heart disease].
Topics: Anti-Arrhythmia Agents; Electrocardiography; Electrocardiography, Ambulatory; Female; Humans; Male; | 1996 |
The in-vivo cardiovascular effects of a putative class III anti-arrhythmic drug, AM 92016.
Topics: Anesthesia, Inhalation; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Guine | 1996 |
Clinical predictors of defibrillation energy requirements.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Coronary Disease; Defi | 1997 |
Proarrhythmic effects of DL- and D-sotalol on the "border zone" between normal and ischemic regions of isolated ventricular myocardium and antiarrhythmic effects on reperfusion.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Guinea Pigs; Heart | 1998 |
Short-term myocardial uptake of d- and l-sotalol in humans: relation to hemodynamic and electrophysiologic effects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Female; Humans; Male; Middle Aged; Myocardial Ischemia; My | 1998 |
Hypotension in patients with coronary disease: can profound hypotensive events cause myocardial ischaemic events?
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Blood Pressure Monitoring, Amb | 1999 |
Ischemia-induced action potential shortening is blunted by d-sotalol in a pig model of reversible myocardial ischemia.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrophysiology; Male; | 2000 |
Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits.
Topics: Action Potentials; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models | 2000 |
Effects of acute global low-flow ischemia on triggered arrhythmias in d-sotalol-induced long Q-T intervals in perfused rabbit hearts.
Topics: Adrenergic beta-Antagonists; Animals; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Condu | 2001 |